2256.HK

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$247M	-61.5%	$-0.35	$-0.57–$-0.23	—	4
2027	$446M	+80.9%	$-0.22	$-1.01–$0.21	—	6
2028	$852M	+91.1%	$-0.06	$-0.09–$-0.03	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-24	$-0.39	$-0.35	+11.8%
2026-03-02	$-0.43	$-0.48	-10.3%
2025-08-04	$0.56	$0.56	+0.0%
2025-03-03	$-0.42	$-0.30	+28.2%
2024-08-12	$-0.37	$0.34	+192.9%
2024-03-12	$-0.57	$-0.37	+34.6%
2023-08-16	$-0.59	$-0.18	+69.1%

DCF fair valuemodel estimate

Intrinsic value

$1.91

Price

$8.47

Implied downside

-77%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
2256.HKAbbisko Cayman Limited	$8.51	-2.24%	$6.1B	—
0775.HKCK Life Sciences International (Holdings), Inc.	$0.54	-1.82%	$5.2B	—
1672.HKAscletis Pharma Inc.	$8.94	-0.67%	$9.4B	—
1931.HKETHK Labs Inc.	$0.49	-1.01%	$785M	—
2142.HKHBM Holdings Limited	$12.73

Abbisko Cayman Limited

Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.

www.abbisko.com

Employees: 286
IPO / List date: Oct 13, 2021
HQ: CN

Held by traders on TradeandTell

No one on the platform currently holds 2256.HK.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 2256.HK as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 2256.HK yet.